Citations

Clear

4510 citation(s) found for "Scott, C".

Are There Differences in 2-Year Outcomes Between Two-Level Anterior Cervical Diskectomy and Fusion Versus Single-Level Anterior Cervical Corpectomy and Fusion to Treat Cervical Myelopathy? A Quality Outcomes Database Study
Berlin, Connor , Mummaneni, Praveen V., Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Tumialán, Luis M. , Turner, Jay D. , Uribe, Juan S. , Haid, Regis W., Yen, Chun-Po , Shaffrey, Mark E., Shaffrey, Mark E , Ibrahim, Sufyan , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Neurosurgery | May 19, 2025 | Volume: 97 | Issue: 5 | Pages: 1091-1099

10.1227/neu.0000000000003518 | PMID 40388528 Get It

BACKGROUND AND OBJECTIVES: There has been limited assessment between anterior cervical diskectomy and fusion (ACDF) and anterior cervical corpectomy and fusion (ACCF) on patient-reported outcome measures (PROMs) in the treatment of cervical spondylotic myelopathy. We sought to compare PROMs from two-level ACDF with single-level ACCF procedures. We evaluate these results in the context of minimum clinically important difference (MCID) thresholds, which have not been performed previously. METHODS: This retrospective analysis of prospectively collected data from the Quality Outcomes Database Spine Collaborative Research Study Group compared two-level ACDF and single-level ACCF at 3-, 12-, and 24 months postoperatively. PROMs included arm pain Numeric Rating Scale, neck pain Numeric Rating Scale, Neck Disability Index, and North American Spine Society Patient Satisfaction Index. Multivariate logistic regression was used to determine differences in perioperative outcomes, as well as the impact of two-level ACDF vs one-level ACCF on PROMs. MCID thresholds were based off previously established limits. RESULTS: Three hundred and thirty patients were included (236 ACDF, 94 ACCF), and the follow-up rate was 82% at 2 years. There was a significantly higher baseline age, American Society of Anesthesiologists grade, proportion of diabetes, osteoarthritis, ambulation dependence, and myelopathy severity in the ACCF cohort. On multivariable analysis, the ACCF group had greater average length of stay and estimated blood loss. There were no significant differences between reoperation rates or nonroutine discharge. There were similar rates of MCID achievement for PROMs at all time points. CONCLUSION: This study suggests that both ACDF and ACCF procedures for cervical spondylotic myelopathy are able to achieve similar, clinically meaningful improvements in PROMs by 2 years. Patients undergoing single-level ACCF have more estimated blood loss and longer length of stay, as well as worse baseline myelopathy. Both procedures have efficacious, durable outcomes. It is reasonable that other factors, such as radiographic characteristics and patient symptoms, may influence patient selection for ACDF vs ACCF.
The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Engaging Community Reviewers: The Geriatric Emergency Care Applied Research (2.0)—Advancing Dementia Care Network Approach
Gifford, Angela , McClellan, Chelsea, Daven, Morgan, Foster, Beverly, Gil, Heidi, Johnson, Jerry , Jobe, Deborah, Carpenter, Christopher R. , Hwang, Ula , Carpenter, Christopher R , Hwang, Ula , Shah, Manish N , McClellan, Chelsea, Ellenbogen, Michael I. , Foster, Beverly, Dresden, Scott M. , Gilmore‐Bykovskyi, Andrea L , Shah, Manish N.

Mayo Clinic

Journal of the American Geriatrics Society | May 16, 2025 | Volume: 73 | Issue: 9 | Pages: 2678-2684

10.1111/jgs.19515 | PMID 40377497 Get It

ABSTRACTA core tenant of the Geriatric Emergency care Applied Research Network 2.0—Advancing Dementia Care (GEAR 2.0‐ADC) is the inclusion of community members during all stages of clinical research. As such, we deliberately integrated and supported patient and public involvement in the evaluation and selection of GEAR 2.0‐ADC Pilot Research Grants by developing and adapting traditional grant application review structures, with input from community members, to create the GEAR 2.0‐ADC Community Review Committee approach. Community members, including persons living with dementia, effectively participated in all three rounds of research grant application review and selection, complementing the traditional scientific review process. The structure and flexibility of the GEAR 2.0‐ADC Community Review Committee approach serve as a model for patient and public grant application review involvement with strong potential for applications across grant reviews in other medical specialties.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis
Loesch, Jack , Hamza, Eyad , Pasricha, Pankaj J. , Nee, Judy , Cline, Michael, MacDougall, James A., Simons, Madison , Brown, J. Trig, Garg, Samita , Hoscheit, Matthew, Gabbard, Scott , Colle, Cyril De, Brown, John T , De Colle, Cyril , Lembo, Anthony , MacDougall, James, Lembo, Anthony

Mayo Clinic

American Journal of Gastroenterology | May 14, 2025 | Volume: 121 | Issue: 2 | Pages: 534-544

10.14309/ajg.0000000000003534 | PMID 40367443 Get It

INTRODUCTION: There is an urgent need for effective and safe treatment of gastroparesis. Metopimazine, a selective, peripherally restricted dopamine D 2 receptor antagonist, is used in France for the symptomatic treatment of nausea and vomiting and chemotherapy-induced nausea and vomiting. The aim of this study is to assess the safety and efficacy of oral NG101, the mesylate salt of metopimazine, for the treatment of gastroparesis. METHODS: We conducted a 12-week phase 2 multicenter trial with NG101 5, 10, and 20 mg 4 times a day versus placebo. The primary end point was the change in mean nausea severity from the Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary (DIGS-DD) during weeks 7–12 of the Treatment Period from baseline. The DIGS-DD measured nausea, abdominal pain, early satiety, postprandial fullness, and vomiting at their worst in the past 24 hours using a 0-10 point numeric rating scale. Patient Global Impression of Change questionnaires, including nausea, were assessed weekly using a 7-point balanced ordinal score. RESULTS: Of 161 randomized participants (45.3% diabetic and 54.7% idiopathic), mean DIGS-DD nausea severity scores decreased from baseline during weeks 7–12 in all treatment groups, but these improvements were not statistically significant compared with placebo. However, there were statistically significant improvements in nausea Patient Global Impression of Change during weeks 1–12 for all treatment groups compared with placebo. Trends in safety and efficacy favored patients with idiopathic gastroparesis compared with those with diabetic gastroparesis. DISCUSSION: While NG101 did not meet statistical significance in its primary end point for reducing nausea severity, it demonstrated a favorable safety profile and significant improvement in some secondary end points. Further study is needed to determine whether NG101 is an effective treatment for patients with idiopathic gastroparesis.
Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal Cancer
Hidalgo, C. , Bogan, Aaron, Hunter, Danielle E., Tasche, Kendall K. , Moore, Eric J. , Neben-Wittich, M.A. , Price, Katharine A., Bayne, Harry E. Fuentes, Abel, Kathryn M. Van , Hidalgo, Cecelia M, Bogan, Aaron W, Bartemes, Kathleen R. , Neben-Wittich, Michelle A, Lester, Scott C. , McGarrah, Patrick W. , Fuentes Bayne, Harry E, Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L. , Daniel, J. , Routman, David M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 14, 2025 | Volume: 151 | Issue: 12 | Pages: 1117

10.1001/jamaoto.2025.1606 | PMID 40367049 Get It

Importance Circulating tumor human papillomavirus DNA (ctHPVDNA) is an important biomarker for the presence of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but little is known about early postoperative kinetics of ctHPVDNA clearance. Objective To investigate early postoperative kinetics of ctHPVDNA in patients with HPV-associated OPSCC. Design, Setting, and Participants This prospective cohort study was conducted at a single tertiary care center from January 4, 2020, to January 26, 2023. Patients with newly diagnosed HPV-associated OPSCC undergoing surgical management were enrolled. HPV status was defined as positive if findings of p16 immunohistochemistry and/or HPV DNA in situ hybridization and/or E6/E7 RNA in situ hybridization were positive. Exclusion criteria included history of prior head and neck cancer and metastatic disease at presentation. Data were analyzed from September 1, 2024, to April 25, 2025. Exposures Transoral robotic surgery with concurrent neck dissection. Main Outcomes and Measures Blood was drawn prior to surgery (pretreatment), 1 to 2 days after surgery (postoperative days 1 to 2), and approximately 2 weeks after surgery (postoperative week 2; range, 8 to 20 days). ctHPVDNA was quantified by a tumor tissue–modified viral (TTMV) HPV DNA test. Correlations were tested between the pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels using Gaussian regression. Concordance between detectability at postoperative day 1 to 2 and postoperative week 2 was explored using negative predictive value and positive predictive value. Results Of 57 included patients with detectable pretreatment TTMV HPV DNA, 51 (89%) were male, and the median (IQR) age was 59 (54-66) years. A total of 35 patients (61%) had blood draws at all 3 time points; 16 (28%) had detectable TTMV HPV DNA on postoperative day 1 to 2. Pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels had a medium positive linear correlation ( r = 0.31; 95% CI, 0.04-0.54). Undetectable TTMV HPV DNA on postoperative day 1 to 2 blood draw had a negative predictive value of 0.95 (95% CI, 0.74-1.00) for an undetectable level on postoperative week 2 blood draw, but a detectable level on postoperative day 1 to 2 blood draw only had a positive predictive value of 0.19 (95% CI, 0.04-0.46). Of the 16 patients with detectable TTMV HPV DNA pretreatment and at postoperative day 1 to 2, only 3 (19%) continued to have detectable TTMV HPV DNA at postoperative week 2. One patient had undetectable levels at postoperative day 1 to 2 and detectable levels at postoperative week 2. Conclusions and Relevance In this study, ctHPVDNA detectability early after surgery did not predict detectability at 2 weeks after surgery. ctHPVDNA clearance early after surgery could predict a negative test at 2 weeks. A negative blood draw finding on postoperative day 1 may be used to omit a postoperative blood draw at 2 weeks for minimal residual disease detection in future clinical trials.
Radiomic Parenchymal Phenotypes of Breast Texture from Mammography and Association with Risk of Breast Cancer
Winham, Stacey J. , Scott, Christopher G. , Gastounioti, Aimilia , Horng, Hannah , Norman, Aaron D. , Mankowski, Walter C. , Pantalone, Lauren , Jensen, Matthew R. , Acciavatti, Raymond J. , Cohen, Eric A. , Brandt, Kathleen R. , Vachon, Celine M. , Scott, Christopher , Gastounioti, Aimilia , Horng, Hannah , Norman, Aaron D , Mankowski, Walter C , Jensen, Matthew R , Acciavatti, Raymond J , Maidment, Andrew D A , Brandt, Kathleen R , Conant, Emily F , Kerlikowske, Karla M , Kontos, Despina , Vachon, Celine M. , Winham, Stacey J , McCarthy, Anne Marie , Maidment, Andrew D. A. , Conant, Emily F. , Kerlikowske, Karla

Mayo Clinic

Radiology | May 13, 2025 | Volume: 315 | Issue: 2 | Pages: No page available

10.1148/radiol.240281 | PMID 40358450 Get It

Radiomic parenchymal phenotypes on mammograms were used to predict breast cancer risk among both Black and White women, notably for false-negative findings and symptomatic interval cancer.
From embedded interprofessional clinics to expanded alcohol-associated liver disease programs
Winder, Gerald Scott , Banerjee, Arpita Goswami, Bryce, Kelly , Fipps, David C. , Hussain, Filza, Omary, Lesley, Patel, Shivali , Rubman, Susan , Shenoy, Akhil , Suzuki, Joji , Zimbrean, Paula C. , Brown, Kimberly , Mellinger, Jessica L. , Hussain, Filza , Im, Gene , Patel, Arpan , Serper, Marina , Shenoy, Akhil , Suzuki, Joji , Abouljoud, Marwan , Mellinger, Jessica , Winder, Scott , Fipps, David C , Arab, Juan Pablo , Patel, Arpan , Serper, Marina

Mayo Clinic

Liver Transplantation | May 13, 2025 | Volume: 31 | Issue: 12 | Pages: 1567-1580

10.1097/lvt.0000000000000638 | PMID 40359009 Get It

Hazardous alcohol use remains a major contributor to acute and chronic liver disease, while alcohol-associated liver disease (ALD) is a leading indication for liver transplantation. In recent years, embedded, interprofessional ALD clinics have improved access to alcohol use disorder care within hepatology and liver transplantation, but more work is needed to meet this challenge. The literature is lacking regarding scaling procedures to provide services for increasingly large ill patient populations. This article begins to fill this gap by describing “expanded ALD care”: broad, innovative, longitudinal, interprofessional care delivery strategies surpassing standalone clinics. Drawing from analogous patient populations served by collaborative models in primary care and comprehensive eating disorder treatment, the expanded ALD care framework proposes practical strategies toward specific innovations: equipoise between biomedical and psychosocial care elements, increased clinician number and reach, long-term patient relationships, harm reduction and palliative care, outreach to external agencies and clinicians, and enhanced support for patients and families. The article also defines attributes of innovative healthcare systems that support expanded ALD care.
A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma
Siontis, Brittany L. , Rice, John D. , Schuetze, Scott M. , Rottmann, Douglas , Angeles, Christina V. , Fox, Amanda K. , Zyczynski, Laurie E. , Hayek, Salim S. , Robinson, Steven I. , Okuno, Scott H. , Ho, Thanh P. , Hayek, Salim , Chugh, Rashmi , Siontis, Brittany L , Robinson, Steven I , Chugh, Rashmi

Mayo Clinic

Clinical Cancer Research | May 13, 2025 | Volume: 31 | Issue: 14 | Pages: 2919-2925

10.1158/1078-0432.ccr-25-0298 | PMID 40358615 Get It

Abstract Purpose: Soft-tissue sarcomas are rare malignancies with poor prognosis and limited systemic treatment options. We conducted a phase II study to assess the efficacy and safety of trabectedin and olaparib in patients with advanced disease. Patients and Methods: Patients with soft-tissue sarcoma who received ≥1 prior therapy were recruited into two cohorts. Cohort 1 included leiomyosarcoma and liposarcoma; cohort 2 included other histologies. All patients received trabectedin (1.1 mg/m2 24-hour infusion every 21 days) and olaparib (150 mg twice daily continuously). The study was conducted using a Simon minimax two-stage design with a primary endpoint of objective response (OR) rate per RECIST 1.1. Results: Twenty-nine (cohort 1, 16; cohort 2, 13) patients enrolled; one patient in cohort 2 was not evaluable. There were no confirmed ORs in cohort 1; the best response was stable disease in 12 (75%) patients and progressive disease in four (25%). Two partial responses were observed in cohort 2 (n = 12). The most common adverse events were fatigue (75%), neutropenia (75%), anemia (68%), and thrombocytopenia (68%). The median progression-free survival and overall survival for all patients were 3.5 (95% confidence interval, 3.3–8.2) and 13.2 months (95% confidence interval, 10.3–20.9), respectively. Next-generation sequencing of 17 tumors revealed multiple abnormalities, most commonly in TP53, RB1, and ATRX. Conclusions: Trabectedin plus olaparib conferred high rates of toxicity and failed to demonstrate ORs in leiomyosarcoma and liposarcoma. Preliminary evidence of clinical benefit in two patients in cohort 2 suggests potential value of either or both drugs in other sarcomas.
Rizatriptan vs Placebo for Attacks of Vestibular Migraine
Eggers, Scott D.Z. , Jen, Joanna C. , Geske, Jennifer R. , Hofschulte, Deanna R., Gonzalez, Gabrielle F , Neff, Brian A., Shepard, Neil T., McCaslin, Devin L. , Baloh, Robert W., Geske, Jennifer , Staab, Jeffrey P. , LeMahieu, Allison , Liu, Honghu

Mayo Clinic

JAMA Neurology | May 12, 2025 | Volume: 82 | Issue: 7 | Pages: 676

10.1001/jamaneurol.2025.1006 | PMID 40354049 Get It

ImportanceVestibular migraine has no established treatments.ObjectiveTo test the efficacy of rizatriptan for treating vestibular migraine attacks.Design, Setting, and ParticipantsThis double-blind, randomized clinical trial of rizatriptan vs placebo was conducted from December 2014 through July 2020 (data analyses in 2021 and sensitivity analyses in 2022 and 2024) at 2 tertiary neurotologic centers. Adults with vestibular migraine were included.InterventionAll participants underwent prospective observation to confirm diagnosis and illness activity and were then randomized in a 2:1 ratio to receive rizatriptan 10 mg or placebo to treat up to 3 vestibular migraine attacks per participant.Main Outcomes and MeasuresParticipants rated symptoms as absent, mild, moderate, or severe at scheduled intervals. Primary outcomes were the percentage of attacks with reductions in vertigo and unsteadiness/dizziness from moderate or severe to absent or mild at 1 hour. Secondary outcomes were the percentage of attacks with complete resolution of vestibular symptoms at 1 hour; reductions in headache and associated symptoms at 1 hour; use of rescue medications after 1 hour; reductions in vestibular, headache, and associated symptoms at 24 hours without rescue medications; treatment satisfaction and quality of life at 48 hours; and rates of serious adverse effects and discontinuation due to adverse effects.ResultsOf 222 total participants (mean [SD] age, 42.3 [11.7] years; 70.7% were women), 134 (60.4%) with active illness treated 307 attacks. Efficacy was tested using 240 attacks with vestibular symptoms rated as moderate or severe when participants took study drug. At 1 hour, rizatriptan did not differ from placebo for reducing vertigo (73/151 [48.3%] vs 50/88 [56.8%] attacks; odds ratio [OR], 0.71 [95% CI, 0.42-1.21]), unsteadiness/dizziness (29/151 [19.2%] vs 11/89 [12.4%] attacks; OR, 1.69 [95% CI, 0.80-3.57]), or any secondary outcomes. Similar percentages of participants in rizatriptan and placebo groups (26.4% for both groups) added rescue remedies after 1 hour. At 24 hours, rizatriptan had medium effects over placebo for unsteadiness/dizziness (OR, 2.65) and motion sensitivity (OR, 3.58). Post hoc analyses of all treated attacks found a medium effect favoring rizatriptan for headache and photophobia or phonophobia at 24 hours. Treatment satisfaction was equivocal. Quality of life was mixed. No participants experienced serious adverse effects or discontinued treatment for adverse effects.Conclusions and RelevanceIn this study, rizatriptan was ineffective at 1 hour for treating vestibular migraine attacks and had limited benefit on symptoms at 24 hours. Findings do not support using rizatriptan for vestibular migraine attacks.Trial RegistrationClinicalTrials.gov Identifier: NCT02447991